Episode Details
Back to Episodes
NurExone Biologic’s U.S. Deal Could Unlock Scalable Exosome Production | NurExone Biologic (TSXV: NRX | OTCQB: NRXBF)
Description
In this episode, NurExone Biologic (TSXV: NRX | OTCQB: NRXBF | FSE: J90) advances its exosome platform toward commercialization with a newly announced LOI aimed at establishing U.S.-based production and distribution capabilities. Listeners will hear CEO Lior Shaltiel explain how this partnership supports both clinical development and near-term commercial opportunities across therapeutics and high-demand adjacent markets.
This discussion covers:
- The role of ExoTop in NurExone’s exosome production platform
- Strategic importance of U.S. manufacturing and distribution infrastructure
- Details behind the LOI and its potential commercial impact
- Expanding applications in therapeutics, aesthetics, and regenerative medicine
Website: https://neurexone.com
Disclaimer: This podcast is made in partnership with NurExone Biologic. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://stockhouse.com/legal/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.